{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T10:03:53Z","timestamp":1768557833906,"version":"3.49.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Vaccines offer an option to treat heroin and prescription opioid abuse and prevent fatal overdoses. Opioid vaccines elicit antibodies that block opioid distribution to the brain and reduce opioid-induced behavioral effects and toxicity. The major limitation to the translation of addiction vaccines is that efficacy is observed only in subjects achieving optimal drug-specific serum antibody levels. This study tested whether efficacy of a vaccine against oxycodone is increased by immunomodulators targeting key cytokine signaling pathways involved in B and T cell lymphocyte activation. Blockage of IL-4 signaling increased vaccine efficacy in blocking oxycodone distribution to the brain and protection against opioid-induced behavior and toxicity in mice. This strategy generalized to a peptide-protein conjugate immunogen, and a tetanus-diphtheria-pertussis vaccine. These data demonstrate that cytokine-based immunomodulators increase efficacy of vaccines against small molecules, peptides and proteins, and identify IL-4 as a pharmacological target for improving efficacy of next-generation vaccines.<\/jats:p>","DOI":"10.1038\/s41598-018-23777-6","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T02:18:25Z","timestamp":1522289905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose"],"prefix":"10.1038","volume":"8","author":[{"given":"Megan","family":"Laudenbach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Baruffaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davis","family":"Seelig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carly","family":"Baehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Pravetoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,3]]},"reference":[{"key":"23777_CR1","doi-asserted-by":"publisher","unstructured":"Rappuoli, R., Pizza, M., Del Giudice, G. & De Gregorio, E. Vaccines, new opportunities for a new society. Proc Natl Acad Sci USA, https:\/\/doi.org\/10.1073\/pnas.1402981111 (2014).","DOI":"10.1073\/pnas.1402981111"},{"key":"23777_CR2","unstructured":"UNODC. World Drug Report 2016 (2016)."},{"key":"23777_CR3","unstructured":"CDC. Wide-ranging OnLine Data for Epidemiologic Research (WONDER), http:\/\/wonder.cdc.gov (2016)."},{"key":"23777_CR4","doi-asserted-by":"publisher","unstructured":"Volkow, N. D. & Collins, F. S. The Role of Science in Addressing the Opioid Crisis. N Engl J Med, https:\/\/doi.org\/10.1056\/NEJMsr1706626 (2017).","DOI":"10.1056\/NEJMsr1706626"},{"key":"23777_CR5","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1080\/21645515.2016.1212785","volume":"12","author":"M Pravetoni","year":"2016","unstructured":"Pravetoni, M. Biologics to treat substance use disorders: Current status and new directions. Hum Vaccin Immunother 12, 3005\u20133019, https:\/\/doi.org\/10.1080\/21645515.2016.1212785 (2016).","journal-title":"Hum Vaccin Immunother"},{"key":"23777_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/bs.irn.2016.02.009","volume":"126","author":"O Ohia-Nwoko","year":"2016","unstructured":"Ohia-Nwoko, O., Kosten, T. A. & Haile, C. N. Animal Models and the Development of Vaccines to Treat Substance Use Disorders. Int Rev Neurobiol 126, 263\u2013291, https:\/\/doi.org\/10.1016\/bs.irn.2016.02.009 (2016).","journal-title":"Int Rev Neurobiol"},{"key":"23777_CR7","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/bcp.12115","volume":"77","author":"T Kosten","year":"2014","unstructured":"Kosten, T., Domingo, C., Orson, F. & Kinsey, B. Vaccines against stimulants: cocaine and MA. Br J Clin Pharmacol 77, 368\u2013374, https:\/\/doi.org\/10.1111\/bcp.12115 (2014).","journal-title":"Br J Clin Pharmacol"},{"key":"23777_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1586\/erv.13.1","volume":"12","author":"S Brimijoin","year":"2013","unstructured":"Brimijoin, S., Shen, X., Orson, F. & Kosten, T. Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse. Expert Rev Vaccines 12, 323\u2013332, https:\/\/doi.org\/10.1586\/erv.13.1 (2013).","journal-title":"Expert Rev Vaccines"},{"key":"23777_CR9","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.tips.2015.07.002","volume":"36","author":"P Skolnick","year":"2015","unstructured":"Skolnick, P. Biologic Approaches to Treat Substance-Use Disorders. Trends Pharmacol Sci 36, 628\u2013635, https:\/\/doi.org\/10.1016\/j.tips.2015.07.002 (2015).","journal-title":"Trends Pharmacol Sci"},{"key":"23777_CR10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1124\/pr.117.013904","volume":"69","author":"PT Bremer","year":"2017","unstructured":"Bremer, P. T. & Janda, K. D. Conjugate Vaccine Immunotherapy for Substance Use Disorder. Pharmacol Rev 69, 298\u2013315, https:\/\/doi.org\/10.1124\/pr.117.013904 (2017).","journal-title":"Pharmacol Rev"},{"key":"23777_CR11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/B978-0-12-420118-7.00014-7","volume":"69","author":"PR Pentel","year":"2014","unstructured":"Pentel, P. R. & LeSage, M. G. New directions in nicotine vaccine design and use. Adv Pharmacol 69, 553\u2013580, https:\/\/doi.org\/10.1016\/B978-0-12-420118-7.00014-7 (2014).","journal-title":"Adv Pharmacol"},{"key":"23777_CR12","doi-asserted-by":"publisher","unstructured":"Diavatopoulos, D. A. & Edwards, K. M. What Is Wrong with Pertussis Vaccine Immunity? Why Immunological Memory to Pertussis Is Failing. Cold Spring Harb Perspect Biol, https:\/\/doi.org\/10.1101\/cshperspect.a029553 (2017).","DOI":"10.1101\/cshperspect.a029553"},{"key":"23777_CR13","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","volume":"33","author":"RL Coffman","year":"2010","unstructured":"Coffman, R. L., Sher, A. & Seder, R. A. Vaccine adjuvants: putting innate immunity to work. Immunity 33, 492\u2013503, https:\/\/doi.org\/10.1016\/j.immuni.2010.10.002 (2010).","journal-title":"Immunity"},{"key":"23777_CR14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/vaccines3020320","volume":"3","author":"A Di Pasquale","year":"2015","unstructured":"Di Pasquale, A., Preiss, S., Tavares Da Silva, F. & Garcon, N. Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines (Basel) 3, 320\u2013343, https:\/\/doi.org\/10.3390\/vaccines3020320 (2015).","journal-title":"Vaccines (Basel)"},{"key":"23777_CR15","doi-asserted-by":"publisher","unstructured":"Pravetoni, M. et al. An oxycodone conjugate vaccine elicits oxycodone-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia. J Pharmacol Exp Ther, https:\/\/doi.org\/10.1124\/jpet.111.189506 (2012).","DOI":"10.1124\/jpet.111.189506"},{"key":"23777_CR16","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1021\/jm3013745","volume":"56","author":"M Pravetoni","year":"2013","unstructured":"Pravetoni, M. et al. Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens. J Med Chem 56, 915\u2013923, https:\/\/doi.org\/10.1021\/jm3013745 (2013).","journal-title":"J Med Chem"},{"key":"23777_CR17","doi-asserted-by":"publisher","first-page":"e101807","DOI":"10.1371\/journal.pone.0101807","volume":"9","author":"M Pravetoni","year":"2014","unstructured":"Pravetoni, M. et al. Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats. PLoS One 9, e101807, https:\/\/doi.org\/10.1371\/journal.pone.0101807 (2014).","journal-title":"PLoS One"},{"key":"23777_CR18","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1016\/j.vaccine.2012.04.101","volume":"30","author":"M Pravetoni","year":"2012","unstructured":"Pravetoni, M. et al. Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats. Vaccine 30, 4617\u20134624, https:\/\/doi.org\/10.1016\/j.vaccine.2012.04.101 (2012).","journal-title":"Vaccine"},{"key":"23777_CR19","doi-asserted-by":"publisher","first-page":"e96547","DOI":"10.1371\/journal.pone.0096547","volume":"9","author":"M Pravetoni","year":"2014","unstructured":"Pravetoni, M. et al. Effect of currently approved carriers and adjuvants on the pre-clinical efficacy of a conjugate vaccine against oxycodone in mice and rats. PLoS One 9, e96547, https:\/\/doi.org\/10.1371\/journal.pone.0096547 (2014).","journal-title":"PLoS One"},{"key":"23777_CR20","doi-asserted-by":"publisher","first-page":"e0184876","DOI":"10.1371\/journal.pone.0184876","volume":"12","author":"MD Raleigh","year":"2017","unstructured":"Raleigh, M. D. et al. Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse. PLoS One 12, e0184876, https:\/\/doi.org\/10.1371\/journal.pone.0184876 (2017).","journal-title":"PLoS One"},{"key":"23777_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nri3128","volume":"12","author":"M McHeyzer-Williams","year":"2012","unstructured":"McHeyzer-Williams, M., Okitsu, S., Wang, N. & McHeyzer-Williams, L. Molecular programming of B cell memory. Nat Rev Immunol 12, 24\u201334, https:\/\/doi.org\/10.1038\/nri3128 (2012).","journal-title":"Nat Rev Immunol"},{"key":"23777_CR22","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1146\/annurev-immunol-020711-075032","volume":"30","author":"GD Victora","year":"2012","unstructured":"Victora, G. D. & Nussenzweig, M. C. Germinal centers. Annu Rev Immunol 30, 429\u2013457, https:\/\/doi.org\/10.1146\/annurev-immunol-020711-075032 (2012).","journal-title":"Annu Rev Immunol"},{"key":"23777_CR23","doi-asserted-by":"publisher","first-page":"5926","DOI":"10.4049\/jimmunol.1500385","volume":"194","author":"M Laudenbach","year":"2015","unstructured":"Laudenbach, M. et al. The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse. J Immunol 194, 5926\u20135936, https:\/\/doi.org\/10.4049\/jimmunol.1500385 (2015).","journal-title":"J Immunol"},{"key":"23777_CR24","doi-asserted-by":"publisher","first-page":"6332","DOI":"10.1016\/j.vaccine.2015.09.015","volume":"33","author":"M Laudenbach","year":"2015","unstructured":"Laudenbach, M., Tucker, A. M., Runyon, S. P., Carroll, F. I. & Pravetoni, M. The frequency of early-activated hapten-specific B cell subsets predicts the efficacy of vaccines for nicotine dependence. Vaccine 33, 6332\u20136339, https:\/\/doi.org\/10.1016\/j.vaccine.2015.09.015 (2015).","journal-title":"Vaccine"},{"key":"23777_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jim.2014.01.010","volume":"405","author":"JJ Taylor","year":"2014","unstructured":"Taylor, J. J., Laudenbach, M., Tucker, A. M., Jenkins, M. K. & Pravetoni, M. Hapten-specific naive B cells are biomarkers of vaccine efficacy against drugs of abuse. J Immunol Methods 405, 74\u201386, https:\/\/doi.org\/10.1016\/j.jim.2014.01.010 (2014).","journal-title":"J Immunol Methods"},{"key":"23777_CR26","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.immuni.2012.02.012","volume":"36","author":"A Ballesteros-Tato","year":"2012","unstructured":"Ballesteros-Tato, A. et al. Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity 36, 847\u2013856, https:\/\/doi.org\/10.1016\/j.immuni.2012.02.012 (2012).","journal-title":"Immunity"},{"key":"23777_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10285","volume":"7","author":"PW McDonald","year":"2016","unstructured":"McDonald, P. W. et al. IL-7 signalling represses Bcl-6 and the TFH gene program. Nat Commun 7, 10285, https:\/\/doi.org\/10.1038\/ncomms10285 (2016).","journal-title":"Nat Commun"},{"key":"23777_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nri3803","volume":"15","author":"S Crotty","year":"2015","unstructured":"Crotty, S. A brief history of T cell help to B cells. Nat Rev Immunol 15, 185\u2013189, https:\/\/doi.org\/10.1038\/nri3803 (2015).","journal-title":"Nat Rev Immunol"},{"issue":"Suppl 2","key":"23777_CR29","doi-asserted-by":"publisher","first-page":"B21","DOI":"10.1016\/j.vaccine.2014.12.082","volume":"33","author":"AO Kamphorst","year":"2015","unstructured":"Kamphorst, A. O., Araki, K. & Ahmed, R. Beyond adjuvants: immunomodulation strategies to enhance T cell immunity. Vaccine 33(Suppl 2), B21\u201328, https:\/\/doi.org\/10.1016\/j.vaccine.2014.12.082 (2015).","journal-title":"Vaccine"},{"key":"23777_CR30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.cytogfr.2014.07.010","volume":"25","author":"C Ranasinghe","year":"2014","unstructured":"Ranasinghe, C., Trivedi, S., Wijesundara, D. K. & Jackson, R. J. IL-4 and IL-13 receptors: Roles in immunity and powerful vaccine adjuvants. Cytokine Growth Factor Rev 25, 437\u2013442, https:\/\/doi.org\/10.1016\/j.cytogfr.2014.07.010 (2014).","journal-title":"Cytokine Growth Factor Rev"},{"key":"23777_CR31","doi-asserted-by":"publisher","first-page":"5703","DOI":"10.1016\/j.vaccine.2014.08.023","volume":"32","author":"RJ Jackson","year":"2014","unstructured":"Jackson, R. J., Worley, M., Trivedi, S. & Ranasinghe, C. Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy. Vaccine 32, 5703\u20135714, https:\/\/doi.org\/10.1016\/j.vaccine.2014.08.023 (2014).","journal-title":"Vaccine"},{"key":"23777_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.coi.2014.08.001","volume":"31","author":"LC Wu","year":"2014","unstructured":"Wu, L. C. & Scheerens, H. Targeting IgE production in mice and humans. Curr Opin Immunol 31, 8\u201315, https:\/\/doi.org\/10.1016\/j.coi.2014.08.001 (2014).","journal-title":"Curr Opin Immunol"},{"key":"23777_CR33","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.clim.2014.09.012","volume":"155","author":"JL Berkowitz","year":"2014","unstructured":"Berkowitz, J. L. et al. Safety, efficacy, and pharmacokinetics\/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia\/lymphoma. Clin Immunol 155, 176\u2013187, https:\/\/doi.org\/10.1016\/j.clim.2014.09.012 (2014).","journal-title":"Clin Immunol"},{"key":"23777_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3109\/00952990.2016.1167215","volume":"42","author":"M Backonja","year":"2016","unstructured":"Backonja, M. et al. Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users. Am J Drug Alcohol Abuse 42, 539\u2013549, https:\/\/doi.org\/10.3109\/00952990.2016.1167215 (2016).","journal-title":"Am J Drug Alcohol Abuse"},{"key":"23777_CR35","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/jcph.235","volume":"54","author":"SC Harris","year":"2014","unstructured":"Harris, S. C. et al. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. J Clin Pharmacol 54, 468\u2013477, https:\/\/doi.org\/10.1002\/jcph.235 (2014).","journal-title":"J Clin Pharmacol"},{"key":"23777_CR36","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1521-0391.2011.00120.x","volume":"20","author":"JD Jones","year":"2011","unstructured":"Jones, J. D., Vosburg, S. K., Manubay, J. M. & Comer, S. D. Oxycodone abuse in New York City: characteristics of intravenous and intranasal users. Am J Addict 20, 190\u2013195, https:\/\/doi.org\/10.1111\/j.1521-0391.2011.00120.x (2011).","journal-title":"Am J Addict"},{"key":"23777_CR37","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/00007691-199212000-00008","volume":"14","author":"KP Leow","year":"1992","unstructured":"Leow, K. P., Smith, M. T., Watt, J. A., Williams, B. E. & Cramond, T. Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. Ther Drug Monit 14, 479\u2013484 (1992).","journal-title":"Ther Drug Monit"},{"key":"23777_CR38","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/clpt.1992.176","volume":"52","author":"KP Leow","year":"1992","unstructured":"Leow, K. P., Smith, M. T., Williams, B. & Cramond, T. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 52, 487\u2013495 (1992).","journal-title":"Clin Pharmacol Ther"},{"key":"23777_CR39","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1365-2125.1991.tb03942.x","volume":"32","author":"R Poyhia","year":"1991","unstructured":"Poyhia, R., Olkkola, K. T., Seppala, T. & Kalso, E. The pharmacokinetics of oxycodone after intravenous injection in adults. Br J Clin Pharmacol 32, 516\u2013518 (1991).","journal-title":"Br J Clin Pharmacol"},{"key":"23777_CR40","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1365-2125.1992.tb04090.x","volume":"33","author":"R Poyhia","year":"1992","unstructured":"Poyhia, R., Seppala, T., Olkkola, K. T. & Kalso, E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 33, 617\u2013621 (1992).","journal-title":"Br J Clin Pharmacol"},{"key":"23777_CR41","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1126\/science.1122927","volume":"311","author":"O Boyman","year":"2006","unstructured":"Boyman, O., Kovar, M., Rubinstein, M. P., Surh, C. D. & Sprent, J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311, 1924\u20131927, https:\/\/doi.org\/10.1126\/science.1122927 (2006).","journal-title":"Science"},{"key":"23777_CR42","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.4049\/jimmunol.151.3.1235","volume":"151","author":"FD Finkelman","year":"1993","unstructured":"Finkelman, F. D. et al. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol 151, 1235\u20131244 (1993).","journal-title":"J Immunol"},{"key":"23777_CR43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.4049\/jimmunol.180.1.44","volume":"180","author":"JD Phelan","year":"2008","unstructured":"Phelan, J. D., Orekov, T. & Finkelman, F. D. Cutting edge: mechanism of enhancement of in vivo cytokine effects by anti-cytokine monoclonal antibodies. J Immunol 180, 44\u201348 (2008).","journal-title":"J Immunol"},{"key":"23777_CR44","doi-asserted-by":"publisher","first-page":"16683","DOI":"10.1073\/pnas.0805054105","volume":"105","author":"G Verdeil","year":"2008","unstructured":"Verdeil, G., Marquardt, K., Surh, C. D. & Sherman, L. A. Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy. Proc Natl Acad Sci USA 105, 16683\u201316688, https:\/\/doi.org\/10.1073\/pnas.0805054105 (2008).","journal-title":"Proc Natl Acad Sci USA"},{"key":"23777_CR45","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.4049\/jimmunol.154.9.4675","volume":"154","author":"JF Urban Jr.","year":"1995","unstructured":"Urban, J. F. Jr., Maliszewski, C. R., Madden, K. B., Katona, I. M. & Finkelman, F. D. IL-4 treatment can cure established gastrointestinal nematode infections in immunocompetent and immunodeficient mice. J Immunol 154, 4675\u20134684 (1995).","journal-title":"J Immunol"},{"key":"23777_CR46","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1365-2125.2008.03327.x","volume":"67","author":"S Fanoe","year":"2009","unstructured":"Fanoe, S., Jensen, G. B., Sjogren, P., Korsgaard, M. P. & Grunnet, M. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro. Br J Clin Pharmacol 67, 172\u2013179, https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03327.x (2009).","journal-title":"Br J Clin Pharmacol"},{"key":"23777_CR47","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0161-5890(95)00119-0","volume":"33","author":"S Kerdine","year":"1996","unstructured":"Kerdine, S., Lebrec, H., Bertoglio, J. & Pallardy, M. Interleukin-4 plays a dominant role in Th1- or Th2-like responses during the primary immune response to the hapten penicillin. Mol Immunol 33, 71\u201377 (1996).","journal-title":"Mol Immunol"},{"key":"23777_CR48","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1002\/eji.1830261213","volume":"26","author":"S Kerdine","year":"1996","unstructured":"Kerdine, S., Pallardy, M., Lamanetre, S., Bertoglio, J. & Lebrec, H. Interleukin-10 and interleukin-4 have similar effects on hapten-specific primary antibody responses to penicillin in vivo. Eur J Immunol 26, 2890\u20132894, https:\/\/doi.org\/10.1002\/eji.1830261213 (1996).","journal-title":"Eur J Immunol"},{"key":"23777_CR49","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1128\/JVI.78.7.3352-3360.2004","volume":"78","author":"AR Mathers","year":"2004","unstructured":"Mathers, A. R. & Cuff, C. F. Role of interleukin-4 (IL-4) and IL-10 in serum immunoglobulin G antibody responses following mucosal or systemic reovirus infection. J Virol 78, 3352\u20133360 (2004).","journal-title":"J Virol"},{"key":"23777_CR50","doi-asserted-by":"publisher","first-page":"10776","DOI":"10.1021\/jm301262z","volume":"55","author":"PT Bremer","year":"2012","unstructured":"Bremer, P. T. & Janda, K. D. Investigating the effects of a hydrolytically stable hapten and a Th1 adjuvant on heroin vaccine performance. J Med Chem 55, 10776\u201310780, https:\/\/doi.org\/10.1021\/jm301262z (2012).","journal-title":"J Med Chem"},{"key":"23777_CR51","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1021\/mp400631w","volume":"11","author":"PT Bremer","year":"2014","unstructured":"Bremer, P. T., Schlosburg, J. E., Lively, J. M. & Janda, K. D. Injection route and TLR9 agonist addition significantly impact heroin vaccine efficacy. Mol Pharm 11, 1075\u20131080, https:\/\/doi.org\/10.1021\/mp400631w (2014).","journal-title":"Mol Pharm"},{"key":"23777_CR52","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.intimp.2013.03.021","volume":"16","author":"MJ McCluskie","year":"2013","unstructured":"McCluskie, M. J. et al. Enhancing immunogenicity of a 3\u2019aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates. Int Immunopharmacol 16, 50\u201356, https:\/\/doi.org\/10.1016\/j.intimp.2013.03.021 (2013).","journal-title":"Int Immunopharmacol"},{"key":"23777_CR53","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1166\/jbn.2015.2156","volume":"11","author":"H Zheng","year":"2015","unstructured":"Zheng, H. et al. Negatively Charged Carbon Nanohorn Supported Cationic Liposome Nanoparticles: A Novel Delivery Vehicle for Anti-Nicotine Vaccine. J Biomed Nanotechnol 11, 2197\u20132210 (2015).","journal-title":"J Biomed Nanotechnol"},{"key":"23777_CR54","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.biomaterials.2016.08.028","volume":"106","author":"Y Hu","year":"2016","unstructured":"Hu, Y. et al. The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine. Biomaterials 106, 228\u2013239, https:\/\/doi.org\/10.1016\/j.biomaterials.2016.08.028 (2016).","journal-title":"Biomaterials"},{"key":"23777_CR55","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1182\/blood-2012-01-380121","volume":"119","author":"P Bruhns","year":"2012","unstructured":"Bruhns, P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119, 5640\u20135649, https:\/\/doi.org\/10.1182\/blood-2012-01-380121 (2012).","journal-title":"Blood"},{"key":"23777_CR56","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3389\/fimmu.2014.00587","volume":"5","author":"JM Fritz","year":"2014","unstructured":"Fritz, J. M. et al. Depletion of tumor-associated macrophages slows the growth of chemically induced mouse lung adenocarcinomas. Front Immunol 5, 587, https:\/\/doi.org\/10.3389\/fimmu.2014.00587 (2014).","journal-title":"Front Immunol"},{"key":"23777_CR57","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.immuni.2012.11.020","volume":"38","author":"D Baumjohann","year":"2013","unstructured":"Baumjohann, D. et al. Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype. Immunity 38, 596\u2013605, https:\/\/doi.org\/10.1016\/j.immuni.2012.11.020 (2013).","journal-title":"Immunity"},{"key":"23777_CR58","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1021\/acschembio.6b00977","volume":"12","author":"A Kimishima","year":"2017","unstructured":"Kimishima, A., Wenthur, C. J., Zhou, B. & Janda, K. D. An Advance in Prescription Opioid Vaccines: Overdose Mortality Reduction and Extraordinary Alteration of Drug Half-Life. ACS Chem Biol 12, 36\u201340, https:\/\/doi.org\/10.1021\/acschembio.6b00977 (2017).","journal-title":"ACS Chem Biol"},{"key":"23777_CR59","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.immuni.2007.07.007","volume":"27","author":"JJ Moon","year":"2007","unstructured":"Moon, J. J. et al. Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 27, 203\u2013213, https:\/\/doi.org\/10.1016\/j.immuni.2007.07.007 (2007).","journal-title":"Immunity"},{"key":"23777_CR60","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.cell.2013.04.007","volume":"153","author":"NJ Tubo","year":"2013","unstructured":"Tubo, N. J. et al. Single Naive CD4(+) T Cells from a Diverse Repertoire Produce Different Effector Cell Types during Infection. Cell 153, 785\u2013796, https:\/\/doi.org\/10.1016\/j.cell.2013.04.007 (2013).","journal-title":"Cell"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23777-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23777-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23777-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T20:54:52Z","timestamp":1693601692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23777-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,3]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["23777"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-23777-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,3]]},"assertion":[{"value":"29 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.P. is the inventor of \u201cCytokine Signaling Immunomodulators and Methods\u201d. Provisional Patent Application No. 62\/334, 167 filed on May 10, 2016 and International Application No. PCT\/US2017\/031907 filed on May 10, 2017. Other authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5508"}}